Reviva Pharmaceuticals Statistics
Share Statistics
Reviva Pharmaceuticals has 46.74M
shares outstanding. The number of shares has increased by 56.22%
in one year.
| Shares Outstanding | 46.74M |
| Shares Change (YoY) | 56.22% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 22.87% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 475 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 3.81M, so 8.19% of the outstanding
shares have been sold short.
| Short Interest | 3.81M |
| Short % of Shares Out | 8.19% |
| Short % of Float | 9.16% |
| Short Ratio (days to cover) | 2.86 |
Valuation Ratios
The PE ratio is -2.01 and the forward
PE ratio is -1.05.
Reviva Pharmaceuticals's PEG ratio is
0.04.
| PE Ratio | -2.01 |
| Forward PE | -1.05 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 73.84 |
| P/FCF Ratio | -1.79 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Reviva Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.01,
with a Debt / Equity ratio of 0.56.
| Current Ratio | 1.01 |
| Quick Ratio | 1.01 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.01 |
| Interest Coverage | -1665.07 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,137,057.29 |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 19.51K |
| Effective Tax Rate | -0.07% |
Stock Price Statistics
The stock price has increased by -72.33% in the
last 52 weeks. The beta is 0.05, so Reviva Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.05 |
| 52-Week Price Change | -72.33% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 50.79 |
| Average Volume (20 Days) | 988,426 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -30.8M |
| Net Income | -29.92M |
| EBITDA | -29.88M |
| EBIT | -29.88M |
| Earnings Per Share (EPS) | -0.9 |
Full Income StatementBalance Sheet
The company has 13.48M in cash and 458.15K in
debt, giving a net cash position of 13.02M.
| Cash & Cash Equivalents | 13.48M |
| Total Debt | 458.15K |
| Net Cash | 13.02M |
| Retained Earnings | -164.27M |
| Total Assets | 15.5M |
| Working Capital | 81.86K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -33.54M
and capital expenditures 0, giving a free cash flow of -33.54M.
| Operating Cash Flow | -33.54M |
| Capital Expenditures | n/a |
| Free Cash Flow | -33.54M |
| FCF Per Share | -1.01 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
